Masters Capital Management LLC Denali Therapeutics Inc. Transaction History
Masters Capital Management LLC
- $2.71 Billion
- Q3 2025
A detailed history of Masters Capital Management LLC transactions in Denali Therapeutics Inc. stock. As of the latest transaction made, Masters Capital Management LLC holds 750,000 shares of DNLI stock, worth $13.1 Million. This represents 0.4% of its overall portfolio holdings.
Number of Shares
750,000
Previous 600,000
25.0%
Holding current value
$13.1 Million
Previous $8.39 Million
29.74%
% of portfolio
0.4%
Previous 0.34%
Shares
2 transactions
Others Institutions Holding DNLI
# of Institutions
259Shares Held
133MCall Options Held
219KPut Options Held
107K-
Black Rock Inc. New York, NY13.2MShares$230 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA12MShares$209 Million0.0% of portfolio
-
Baillie Gifford & CO11.6MShares$202 Million0.13% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD5.64MShares$98.3 Million0.05% of portfolio
-
Ubs Asset Management Americas Inc Chicago, IL5.47MShares$95.3 Million0.02% of portfolio
About Denali Therapeutics Inc.
- Ticker DNLI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 134,174,000
- Market Cap $2.34B
- Description
- Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...